TLTFF
Theralase Closes C$3.6M Financing for Ruvidar Development
Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF) has closed a brokered private placement that raised gross proceeds of C$3.555 million, providing additional capital for its cancer and antiviral development programs. According to the August 24 announcement, Theralase issued 14,812,500 units at C$0.24 per unit. Each unit contains one common share and one warrant exercisable at…
